We developed a novel GRG signature of six GRGs, including CACNA1H, CHPF, IRS2, NT5E, SDC1 and ATP6AP1, to predict survival and guide individual therapy in breast cancer. This evidence concerns the gene IRS2 and breast carcinoma.